BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34716318)

  • 1. PSMC2 knockdown suppressed tumor progression of skin cutaneous melanoma.
    Yang Y; Qi F; Wei C; Liu J; Zhang Y; Luan W; Gu J
    Cell Death Discov; 2021 Oct; 7(1):323. PubMed ID: 34716318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMC2 knockdown exerts an anti-tumor role in nasopharyngeal carcinoma through regulating AKT signaling pathway.
    Su J; Hu S; Ding S; Feng K
    Cell Cycle; 2023 Nov; 22(21-22):2381-2391. PubMed ID: 38123344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GBP2 Is a Favorable Prognostic Marker of Skin Cutaneous Melanoma and Affects Its Progression via the Wnt/β-catenin Pathway.
    Ji G; Luo B; Chen L; Shen G; Tian T
    Ann Clin Lab Sci; 2021 Nov; 51(6):772-782. PubMed ID: 34921030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing of Proteasome 26S Subunit ATPase 2 Regulates Colorectal Cancer Cell Proliferation, Apoptosis, and Migration.
    He J; Xing J; Yang X; Zhang C; Zhang Y; Wang H; Xu X; Wang H; Cao Y; Xu H; Zhang C; Wang C; Yu E
    Chemotherapy; 2019; 64(3):146-154. PubMed ID: 31715603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of PSMC2 inhibits development and metastasis of prostate cancer through regulating proliferation, apoptosis and migration.
    Chen Q; Fu L; Hu J; Guo G; Xie A
    Cancer Cell Int; 2021 Apr; 21(1):235. PubMed ID: 33902600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanoma.
    He S; Ding Y; Ji Z; Yuan B; Chen J; Ren W
    Cancer Cell Int; 2023 Jun; 23(1):122. PubMed ID: 37344870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSMC2 Regulates Cell Cycle Progression Through the p21/Cyclin D1 Pathway and Predicts a Poor Prognosis in Human Hepatocellular Carcinoma.
    Liu Y; Chen H; Li X; Zhang F; Kong L; Wang X; Bai J; Wu X
    Front Oncol; 2021; 11():607021. PubMed ID: 33718159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Overexpression of SLC25A13 Predicts Poor Prognosis and Is Correlated with Immune Cell Infiltration in Patients with Skin Cutaneous Melanoma.
    Lv Y; Yuan CH; Han LY; Huang GR; Ju LC; Chen LH; Han HY; Zhang C; Zeng LH
    Dis Markers; 2022; 2022():4091978. PubMed ID: 35607442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU).
    Wang Y; Zhu M; Li J; Xiong Y; Wang J; Jing H; Gu Y
    Cell Death Dis; 2021 Jul; 12(7):690. PubMed ID: 34244472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidine Kinase 1 Drives Skin Cutaneous Melanoma Malignant Progression and Metabolic Reprogramming.
    Zuo S; Wang H; Li L; Pan H; Lu L
    Front Oncol; 2022; 12():802807. PubMed ID: 35311151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of the paired box gene 3 inhibits the progression of skin cutaneous melanoma by inhibiting c-MET tyrosine kinase : PAX3 downregulation inhibits melanoma progression.
    Zhang K; Yu C; Tian R; Zhang W; Tang S; Wang G
    Mol Biol Rep; 2022 Oct; 49(10):9137-9145. PubMed ID: 36057879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AURKA is a prognostic potential therapeutic target in skin cutaneous melanoma modulating the tumor microenvironment, apoptosis, and hypoxia.
    Long S; Zhang XF
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3089-3107. PubMed ID: 35870015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients.
    Huang B; Han W; Sheng ZF; Shen GL
    Cancer Cell Int; 2020; 20():195. PubMed ID: 32508531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSMC2 is overexpressed in glioma and promotes proliferation and anti-apoptosis of glioma cells.
    Zheng X; Wang Y; Wang D; Wan J; Qin X; Mu Z; Hu N
    World J Surg Oncol; 2022 Mar; 20(1):84. PubMed ID: 35287689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DIRAS2 Is a Prognostic Biomarker and Linked With Immune Infiltrates in Melanoma.
    Xue W; Zhu H; Liu H; He H
    Front Oncol; 2022; 12():799185. PubMed ID: 35651810
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Lu JJ; Chen FJ; Li Y; Xu X; Peng C; Yu N; Su LN; Tang L
    Ann Transl Med; 2022 Jan; 10(2):68. PubMed ID: 35282044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower miR-630 expression predicts poor prognosis of osteosarcoma and promotes cell proliferation, migration and invasion by targeting PSMC2.
    Li GW; Yan X
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):1915-1925. PubMed ID: 30915734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSMC2 promotes the progression of gastric cancer via induction of RPS15A/mTOR pathway.
    Liu T; Zhang J; Chen H; Bianba T; Pan Y; Wang X; Jiang Y; Yang Z
    Oncogenesis; 2022 Mar; 11(1):12. PubMed ID: 35256584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LSM2 is associated with a poor prognosis and promotes cell proliferation, migration, and invasion in skin cutaneous melanoma.
    Sun X; Zhang J; Hu J; Han Q; Ge Z
    BMC Med Genomics; 2023 Jun; 16(1):129. PubMed ID: 37312186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of NLRP3 in the prognosis and immune infiltrates of skin cutaneous melanoma (SKCM).
    Wu S; Zang Q; Dai B
    Transl Cancer Res; 2021 Apr; 10(4):1692-1702. PubMed ID: 35116494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.